Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor

This article was originally published here

“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D.,

The post Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply